TOP TEN perturbations for 38954_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38954_at
Selected probe(set): 205946_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38954_at (205946_at) across 6674 perturbations tested by GENEVESTIGATOR:

glioma study 17 (oligoastrocytoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):2.787815
Number of Samples:2 / 4
Experimental glioma study 17 (oligoastrocytoma; unsorted)
Brain cells isolated from low grade oligoastrocytoma (grade II). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

brain tumor study 1 (pilocytic astrocytoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-1.6996984
Number of Samples:15 / 46
Experimental brain tumor study 1 (pilocytic astrocytoma)
Primary tumor tissue sample from the brain of patients with pilocytic astrocytoma.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.6208506
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

brain tumor study 1 (glioblastoma) / brain tumor study 1 (ependymoma)

Relative Expression (log2-ratio):-1.565525
Number of Samples:34 / 46
Experimental brain tumor study 1 (glioblastoma)
Primary tumor tissue sample from the brain of patients with glioblastoma multiformae.
Control brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.50595
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.4829168
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

pancreatic cancer study 3 (ipmn) / normal pancreas tissue

Relative Expression (log2-ratio):-1.4145727
Number of Samples:3 / 6
Experimental pancreatic cancer study 3 (ipmn)
Intraductal papillary mucinous neoplasm from patients with pancreatic cancer.
Control normal pancreas tissue
Normal human pancreatic tissue.

ovarian tumor study 11 (borderline) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-1.4098682
Number of Samples:8 / 6
Experimental ovarian tumor study 11 (borderline)
Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

hepatitis C study 6 (under treatment; non-responder) / hepatitis C study 6 (before treatment)

Relative Expression (log2-ratio):1.4017782
Number of Samples:5 / 9
Experimental hepatitis C study 6 (under treatment; non-responder)
Microdissected liver-infiltrating lymphocyte (lilym) samples obtained after liver tissue biopsy from chronic hepatitis C (CH-C) patients after treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib) in combination. Patients received IFN-a 2b (6 MU , every day for 2 weeks, then three times a week for 22 weeks) and Ribavirin (10–13 mg/kg/day) combination therapy for 24 weeks. Individuals had no treatment success and were for that non-responders after HCV viremia detected at the cessation of therapy.
Control hepatitis C study 6 (before treatment)
Microdissected liver-infiltrating lymphocyte (lilym) samples obtained after liver tissue biopsy from chronic hepatitis C (CH-C) patients before treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib).

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.3920898
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.